O	0	3	Use
O	4	6	of
O	7	8	a
B-intervention	9	12	web
I-intervention	12	13	-
I-intervention	13	18	based
I-intervention	19	22	app
O	23	25	to
O	26	33	improve
O	34	40	breast
O	41	47	cancer
O	48	55	symptom
O	56	66	management
O	67	70	and
O	71	80	adherence
O	81	84	for
O	85	94	aromatase
O	95	105	inhibitors
O	105	106	:
O	107	108	a
O	109	119	randomized
O	120	130	controlled
O	131	142	feasibility
O	143	148	trial
O	148	149	.

O	150	153	For
O	154	168	postmenopausal
O	169	174	women
O	175	179	with
O	180	187	hormone
O	188	196	receptor
O	196	197	-
O	197	205	positive
O	206	212	breast
O	213	219	cancer
O	219	220	,
O	221	225	long
O	225	226	-
O	226	230	term
O	231	234	use
O	235	237	of
O	238	247	aromatase
O	248	258	inhibitors
O	259	260	(
O	260	263	AIs
O	263	264	)
O	265	278	significantly
O	279	286	reduces
O	287	290	the
O	291	295	risk
O	296	298	of
O	299	305	cancer
O	306	316	recurrence
O	317	320	and
O	321	329	improves
O	330	338	survival
O	338	339	.

O	340	345	Still
O	345	346	,
O	347	351	many
O	352	360	patients
O	361	364	are
O	365	376	nonadherent
O	377	380	due
O	381	383	to
O	384	391	adverse
O	392	396	side
O	397	404	effects
O	404	405	.

O	406	408	We
O	409	418	conducted
O	419	420	a
O	421	426	pilot
O	427	437	randomized
O	438	448	controlled
O	449	454	trial
O	455	457	to
O	458	462	test
O	463	466	the
O	467	470	use
O	471	473	of
O	474	475	a
O	476	479	web
O	479	480	-
O	480	485	based
O	486	497	application
O	498	499	(
O	499	502	app
O	502	503	)
O	504	512	designed
O	513	517	with
O	518	521	and
O	522	529	without
O	530	536	weekly
O	537	546	reminders
O	547	550	for
O	551	559	patients
O	560	562	to
O	563	569	report
O	570	574	real
O	574	575	-
O	575	579	time
O	580	588	symptoms
O	589	592	and
O	593	595	AI
O	596	599	use
O	600	607	outside
O	608	610	of
O	611	617	clinic
O	618	624	visits
O	625	629	with
O	630	635	built
O	635	636	-
O	636	638	in
O	639	645	alerts
O	646	648	to
O	649	657	patients
O	657	658	'
O	659	667	oncology
O	668	677	providers
O	677	678	.

O	679	682	Our
O	683	687	goal
O	688	691	was
O	692	694	to
O	695	702	improve
O	703	710	symptom
O	711	717	burden
O	718	721	and
O	722	732	medication
O	733	742	adherence
O	742	743	.

B-total-participants	744	749	Forty
I-total-participants	749	750	-
I-total-participants	750	754	four
B-eligibility	755	760	women
I-eligibility	761	765	with
I-eligibility	766	771	early
I-eligibility	771	772	-
I-eligibility	772	777	stage
I-eligibility	778	784	breast
I-eligibility	785	791	cancer
I-eligibility	792	795	and
I-eligibility	796	797	a
I-eligibility	798	801	new
I-eligibility	802	804	AI
I-eligibility	805	817	prescription
O	818	822	were
O	823	833	randomized
O	834	836	to
O	837	843	either
O	844	846	an
O	847	850	App
O	850	851	+
O	851	859	Reminder
O	860	861	(
O	861	867	weekly
O	868	877	reminders
O	878	880	to
O	881	884	use
O	885	888	app
O	888	889	)
O	890	892	or
O	893	895	an
B-control	896	899	App
I-control	900	901	(
I-control	901	903	no
I-control	904	913	reminders
I-control	913	914	)
I-control	915	920	group
O	920	921	.

O	922	925	Pre
O	925	926	-
O	927	930	and
O	931	935	post
O	935	936	-
O	936	946	assessment
O	947	951	data
O	952	956	were
O	957	966	collected
O	967	971	from
O	972	975	all
O	976	988	participants
O	988	989	.

O	990	1002	Participants
O	1003	1005	in
O	1006	1009	the
O	1010	1013	App
O	1013	1014	+
O	1014	1022	Reminder
O	1023	1028	group
O	1029	1032	had
O	1033	1039	higher
B-outcome	1040	1046	weekly
I-outcome	1047	1050	app
I-outcome	1051	1056	usage
I-outcome	1057	1061	rate
O	1062	1063	(
B-iv-bin-percent	1063	1065	74
O	1066	1068	vs
O	1068	1069	.
B-cv-bin-percent	1070	1072	38
I-cv-bin-percent	1072	1073	%
O	1073	1074	,
O	1075	1076	p
O	1077	1078	<
O	1079	1080	0
O	1080	1081	.
O	1081	1083	05
O	1083	1084	)
O	1085	1091	during
O	1092	1095	the
O	1096	1108	intervention
O	1109	1112	and
O	1113	1121	reported
O	1122	1128	higher
B-outcome	1129	1131	AI
I-outcome	1132	1141	adherence
O	1142	1144	at
O	1145	1146	8
O	1147	1152	weeks
O	1153	1154	(
B-iv-bin-percent	1154	1157	100
O	1158	1160	vs
O	1160	1161	.
B-cv-bin-percent	1162	1164	72
I-cv-bin-percent	1164	1165	%
O	1165	1166	,
O	1167	1168	p
O	1169	1170	<
O	1171	1172	0
O	1172	1173	.
O	1173	1175	05
O	1175	1176	)
O	1176	1177	.

B-outcome	1178	1185	Symptom
I-outcome	1186	1192	burden
I-outcome	1193	1201	increase
O	1202	1205	was
O	1206	1212	higher
O	1213	1216	for
O	1217	1220	the
O	1221	1224	App
O	1225	1230	group
O	1231	1239	compared
O	1240	1242	to
O	1243	1246	the
O	1247	1250	App
O	1250	1251	+
O	1251	1259	Reminder
O	1260	1265	group
O	1266	1269	but
O	1270	1273	did
O	1274	1277	not
O	1278	1283	reach
O	1284	1295	statistical
O	1296	1308	significance
O	1308	1309	.

O	1310	1316	Weekly
O	1317	1326	reminders
O	1327	1329	to
O	1330	1333	use
O	1334	1335	a
O	1336	1339	web
O	1339	1340	-
O	1340	1345	based
O	1346	1349	app
O	1350	1352	to
O	1353	1359	report
O	1360	1362	AI
O	1363	1372	adherence
O	1373	1376	and
O	1377	1386	treatment
O	1386	1387	-
O	1387	1394	related
O	1395	1403	symptoms
O	1404	1416	demonstrated
O	1417	1428	feasibility
O	1429	1432	and
O	1433	1441	improved
O	1442	1447	short
O	1447	1448	-
O	1448	1452	term
O	1453	1455	AI
O	1456	1465	adherence
O	1465	1466	,
O	1467	1472	which
O	1473	1476	may
O	1477	1483	reduce
O	1484	1491	symptom
O	1492	1498	burden
O	1499	1502	for
O	1503	1508	women
O	1509	1513	with
O	1514	1520	breast
O	1521	1527	cancer
O	1528	1531	and
O	1532	1533	a
O	1534	1537	new
O	1538	1540	AI
O	1541	1553	prescription
O	1553	1554	.

O	1555	1557	If
O	1558	1563	short
O	1563	1564	-
O	1564	1568	term
O	1569	1574	gains
O	1575	1577	in
O	1578	1587	adherence
O	1588	1595	persist
O	1595	1596	,
O	1597	1601	this
O	1602	1605	low
O	1605	1606	-
O	1606	1610	cost
O	1611	1623	intervention
O	1624	1629	could
O	1630	1637	improve
O	1638	1646	survival
O	1647	1655	outcomes
O	1656	1659	for
O	1660	1665	women
O	1666	1670	with
O	1671	1677	breast
O	1678	1684	cancer
O	1684	1685	.

O	1686	1687	A
O	1688	1694	larger
O	1694	1695	,
O	1696	1700	long
O	1700	1701	-
O	1701	1705	term
O	1706	1711	study
O	1712	1718	should
O	1719	1726	examine
O	1727	1729	if
O	1730	1732	AI
O	1733	1742	adherence
O	1743	1746	and
O	1747	1754	symptom
O	1755	1761	burden
O	1762	1774	improvements
O	1775	1782	persist
O	1783	1786	for
O	1787	1788	a
O	1789	1790	5
O	1790	1791	-
O	1791	1795	year
O	1796	1805	treatment
O	1806	1812	period
O	1812	1813	.
